Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Lynparza Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer

americanpharmaceuticalreviewDecember 20, 2018

Tag: Lynparza , FDA , BRCA-Mutated , ovarian cancer

PharmaSources Customer Service